Instead of building a consumer brand from scratch, a technologically innovative but unknown company can license its core tech to an established player. This go-to-market strategy leverages the partner's brand equity and distribution to reach customers faster and validate the technology without massive marketing spend.

Oshkosh structures partnerships to own IP developed jointly with a startup, then licenses it back. This approach, outlined in the initial NDA, gives the large corporation control over patent defense while providing the startup with usage rights, often with market-specific limitations.

When disrupting a market, selling enabling tools to incumbents (e.g., research agencies) is less effective than competing directly. Incumbents have misaligned incentives and are often low-intent "tire kickers," whereas their end-clients will readily switch for a better, faster, cheaper solution.

The value of a patent extends beyond simple protection. It allows a company to escape commoditization and command higher prices. For startups, patents are tangible assets that justify higher valuations. In legal disputes, they provide crucial leverage for negotiating settlements with competitors.

The core conflict is whether a startup can achieve mass distribution before the incumbent can replicate its core innovation. Historically, incumbents have an advantage because they eventually catch up on technology. AI may accelerate this, making a startup's unique and rapid path to acquiring customers more critical than ever.

Inflammatics initially tried to license its technology but was rejected by major diagnostic firms. The pitch—to build new capabilities and a new platform to displace their own multi-billion dollar microbiology tests—was a classic innovator's dilemma. This refusal by incumbents to disrupt themselves forced the founders to start their own company.

Holding a patent provides no inherent protection. Its value is only realized through active, and expensive, legal defense against infringers. Therefore, a startup's focus should be on building a profitable business first to generate the capital needed to enforce its IP.

When Gillette sued Dollar Shave Club, Michael Dubin understood it was more than a patent dispute. He recognized it as a classic incumbent playbook move: use legal battles to drain a startup's resources and make it appear unattractive to potential investors and acquirers. This framing helps founders contextualize and endure such attacks.

Early-stage MedTech founders should deeply study existing patents in their field. This research goes beyond ensuring freedom to operate; it provides a strategic map of the competitive landscape, revealing opportunities for iteration, new combinations, and a stronger foundation for future filings.